Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229272 | 1.00 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DUSP30 | |
| SCHEMBL2575862 | 0.86 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DUSP30 | |
| SCHEMBL4199136 | 0.85 | ALDH1A1 (0.41) | — | |
| SCHEMBL2276593 | 0.81 | PDE4B (0.57) | PDE4BPDE4APDE4CPDE4DUSP30 | |
| SCHEMBL16286535 | 0.79 | NAMPT (0.41) | PDE4BUSP30PIK3CDRORC | |
| SCHEMBL21761042 | 0.78 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DUSP30 | |
| SCHEMBL30271952 | 0.78 | PDE4B (0.47) | PDE4BUSP30STSRORC | |
| SCHEMBL16296027 | 0.78 | PIN1 (0.42) | PDE4BUSP30PIK3CDRORC | |
| SCHEMBL4193344 | 0.77 | KDM4E (0.39) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4225725 | 0.77 | KDM4E (0.39) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PDE4B 1799/4885PDE4A 1644/4885PDE4C 2287/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PDE4B 1851/4885PDE4A 1636/4885PDE4C 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.